Treatment strategies in mucous membrane pemphigoid

Neff, Ann G.

doi:10.2147/tcrm.s1140

Cited by 51 publications

(53 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[2] A multidisciplinary approach is essential in the management of MMP. Early recognition of this disorder and treatment may reduce disease-related complications.…”

Section: Discussionmentioning

confidence: 99%

Coexistence of mucous membrane pemphigoid and vitiligo

Aithal

Ganguly

Kuruvila

2014

Indian Dermatol Online J

View full text Add to dashboard Cite

Mucous membrane pemphigoid describes a rare heterogeneous group of chronic, inflammatory, mucous membrane-dominated, subepithelial blistering diseases that manifest a varying constellation of oral, ocular, skin, genital, nasopharyngeal, esophageal, and laryngeal lesions. Life-threatening airway obstruction and sight-threatening ocular scarring can occur in this condition, which is rarely reported in Indian literature. Vitiligo is another acquired autoimmune disorder characterized by loss of melanocytes. Vitiligo is associated with a number of disorders also considered to be autoimmune. Here we report a very rare coexistence of MMP and vitiligo, the first such report from India.

show abstract

“…[2] A multidisciplinary approach is essential in the management of MMP. Early recognition of this disorder and treatment may reduce disease-related complications.…”

Section: Discussionmentioning

confidence: 99%

Coexistence of mucous membrane pemphigoid and vitiligo

Aithal

Ganguly

Kuruvila

2014

Indian Dermatol Online J

View full text Add to dashboard Cite

show abstract

“…Choice of appropriate treatment depends on several factors including site involved, severity of disease, and its progression. [9] Topical and systemic treatments are usually used for mild and severe MMP, respectively. In patients with more severe and progressive diseases, a combination of both topical and systemic treatment may be required to control disease progression.…”

Section: Methodsmentioning

confidence: 99%

The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature

Tavakolpour

2016

J Res Med Sci

View full text Add to dashboard Cite

Background:Mucous membrane pemphigoid (MMP) is considered an autoimmune blistering disease that predominantly affects mucous membranes. Various treatments are available for controlling the diseases, but not all of them may respond.Materials and Methods:PubMed and Google Scholar were searched for all the associated studies until 2015, using the keywords such as “cicatricial pemphigoid” or “ocular pemphigoid” or “mucous membrane pemphigoid” or “MMP” and “intravenous immunoglobulin” or “IVIg” to find all the relevant studies. The last search update was for September 2, 2015. Among the searched items, only English studies were included in the review.Results:After excluding nonrelevant studies, 13 studies with a total number of seventy patients with MMP who were under treatment with IVIg were analyzed. The 65 patients responded completely, one did not respond, two had partially responded, and the remaining two patients stopped IVIg therapy, which resulted in ocular cicatricial pemphigoid progression. Majority of the studies reported mild adverse effects while two of them did not report any unwanted side effect. The most common side effect was headache, followed by nausea. Most of the patients who had a cessation of IVIg therapy before achieving clinical remission experienced the disease progression.Conclusion:Overall, it can be concluded that IVIg therapy was very helpful in treatment of MMP patients who did not respond to conventional therapy or stopped using them for various side effects. Adverse effects associated with IVIg therapy were considerably lower than conventional therapy that can lead toward treatment with this agent in patients who suffer from severe side effects.

show abstract

“…Dosages range from 1 to 2.5 mg/kg/day in oral form or can be given in monthly IV pulses of 0.5-1 g/m 2 of body surface area when rapid control is desired [ 11 ]. A recent Cochrane review commented that if appropriately used and monitored, cyclophosphamide may be safer than long-term corticosteroid treatment in MMP [ 10 ].…”

Section: Mucous Membrane Pemphigoidmentioning

confidence: 99%